Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By [...]
Contributing Authors: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD and Manager, Precision Medicine & Navigation, Matthew Reiss, MSE, PhD Each year, researchers, physicians, and industry partners gather at the European Society for Medical Oncology [...]
On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from [...]
Seeking insights from the causes of lung cancer to support for family caregivers Heather Law, MA, is seeking answers. She wants to understand why some people get lung cancer and others don’t. She’s anxious to learn how treatments change [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care [...]
Author: Lung Cancer Registry Associate Director, Heather Law, MA Family caregivers often experience emotional distress and neglect their own well-being while caring for a loved one. Preliminary findings from GO2’s Lung Cancer Registry Caregiver Survey were presented at the 2023 World Conference on [...]
Author: GO2 for Lung Cancer's Specialist, Science & Research, Brittney Nichols MPH, BSN-RN The IASLC annual World Conference on Lung Cancer (WCLC) unites lung cancer professionals from across the world to connect and share insights. This goes beyond the [...]
Author: GO2 for Lung Cancer Treatment and Trials Navigator, Renee Botello MSc Tagrisso (osimertinib) has been the treatment of choice and effective standard of care option for the treatment of EGFR+ non-small cell lung cancer (NSCLC) since its FDA [...]
On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who [...]